Biomarkers for immune intervention trials in type 1 diabetes

Clinical Immunology

Volumn 149, Issue 3, 2013, Pages 286-296

  Mallone, Roberto ^a,b,c   Roep, Bart O ^d,e  

^a INSTITUT COCHIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Service de Diabé tologie   (France)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e National Diabetes Expert Center   (Netherlands)

Author keywords

Autoantibodies; C peptide; Endpoint; T cells

Indexed keywords

BIOLOGICAL MARKER; HEMOGLOBIN A1C; INSULIN;

AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; DISEASE ACTIVITY; DISEASE COURSE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULITIS; LYMPHOCYTIC INFILTRATION; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; T LYMPHOCYTE;

AUTOANTIBODIES; C-PEPTIDE; ENDPOINT; T CELLS;

AUTOANTIBODIES; BIOLOGICAL MARKERS; C-PEPTIDE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOTHERAPY; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; T-LYMPHOCYTES;

EID: 84887026167     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.02.009     Document Type: Review

References (75)

1. Roep B.O., Buckner J., Sawcer S., Toes R., Zipp F. The problems and promises of research into human immunology and autoimmune disease. Nat. Med. 2012, 18:48-53.
2. Di Lorenzo T.P., Peakman M., Roep B.O. Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clin. Exp. Immunol. 2007, 148:1-16.
3. Wenzlau J.M., Juhl K., Yu L., Moua O., Sarkar S.A., Gottlieb P., Rewers M., Eisenbarth G.S., Jensen J., Davidson H.W., Hutton J.C. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17040-17045.
4. Scotto M., Afonso G., Larger E., Raverdy C., Lemonnier F.A., Carel J.C., Dubois-Laforgue D., Baz B., Levy D., Gautier J.F., Launay O., Bruno G., Boitard C., Sechi L.A., Hutton J.C., Davidson H.W., Mallone R. Zinc transporter (ZnT)8(186-194) is an immunodominant CD8 (+) T cell epitope in HLA-A2 (+) type 1 diabetic patients. Diabetologia 2012, 55:2026-2031.
5. Roep B.O. T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Diabetes 1996, 45:1147-1156.
6. Bingley P.J., Bonifacio E., Ziegler A.G., Schatz D.A., Atkinson M.A., Eisenbarth G.S. Proposed guidelines on screening for risk of type 1 diabetes. Diabetes Care 2001, 24:398.
7. Culina S., Mallone R. Immune biomarkers in immunotherapeutic trials for type 1 diabetes: Cui prodest?. Diabetes Metab. 2012, 38:379-385.
8. Coppieters K.T., Dotta F., Amirian N., Campbell P.D., Kay T.W., Atkinson M.A., Roep B.O., von Herrath M.G. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 2012, 209:51-60.
9. Eisenbarth G.S. Banting Lecture 2009: an unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes 2010, 59:759-774.
10. Voltarelli J.C., Couri C.E., Stracieri A.B., Oliveira M.C., Moraes D.A., Pieroni F., Coutinho M., Malmegrim K.C., Foss-Freitas M.C., Simoes B.P., Foss M.C., Squiers E., Burt R.K. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007, 297:1568-1576.
11. Mallone R., Brezar V. To B or not to B: (anti)bodies of evidence on the crime scene of type 1 diabetes?. Diabetes 2011, 60:2020-2022.
12. Sherry N., Hagopian W., Ludvigsson J., Jain S.M., Wahlen J., Ferry R.J., Bode B., Aronoff S., Holland C., Carlin D., King K.L., Wilder R.L., Pillemer S., Bonvini E., Johnson S., Stein K.E., Koenig S., Herold K.C., Daifotis A.G. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011, 378:487-497.
13. Bach J.F. Anti-CD3 antibodies for type 1 diabetes: beyond expectations. Lancet 2011, 378:459-460.
14. Toma A., Haddouk S., Briand J.P., Camoin L., Gahery H., Connan F., Dubois-Laforgue D., Caillat-Zucman S., Guillet J.G., Carel J.C., Muller S., Choppin J., Boitard C. Recognition of a subregion of human proinsulin by class I-restricted T cells in type 1 diabetic patients. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:10581-10586.
15. + T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes 2007, 56:613-621.
16. + T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010, 59:1721-1730.
17. Scotto M., Afonso G., Osterbye T., Larger E., Luce S., Raverdy C., Novelli G., Bruno G., Gonfroy-Leymarie C., Launay O., Lemonnier F.A., Buus S., Carel J.C., Boitard C., Mallone R. HLA-B7-restricted islet epitopes are differentially recognized in type 1 diabetic children and adults and form weak peptide-HLA complexes. Diabetes 2012, 61:2546-2555.
18. Pinkse G.G., Tysma O.H., Bergen C.A., Kester M.G., Ossendorp F., van Veelen P.A., Keymeulen B., Pipeleers D., Drijfhout J.W., Roep B.O. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18425-18430.
19. + T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice. J. Immunol. 2008, 180:5430-5438.
20. Arif S., Tree T.I., Astill T.P., Tremble J.M., Bishop A.J., Dayan C.M., Roep B.O., Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 2004, 113:451-463.
21. Arif S., Moore F., Marks K., Bouckenooghe T., Dayan C.M., Planas R., Vives-Pi M., Powrie J., Tree T., Marchetti P., Huang G.C., Gurzov E.N., Pujol-Borrell R., Eizirik D.L., Peakman M. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes 2011, 60:2112-2119.
22. + T cells show characteristic gene expression profiles in human type 1 diabetes. Diabetes 2011, 60:3289-3299.
23. Skowera A., Ellis R.J., Varela-Calvino R., Arif S., Huang G.C., Van-Krinks C., Zaremba A., Rackham C., Allen J.S., Tree T.I., Zhao M., Dayan C.M., Sewell A.K., Unger W., Drijfhout J.W., Ossendorp F., Roep B.O., Peakman M. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 2008, 118:3390-3402.
24. Kronenberg D., Knight R.R., Estorninho M., Ellis R.J., Kester M.G., de Ru A., Eichmann M., Huang G.C., Powrie J., Dayan C.M., Skowera A., van Veelen P.A., Peakman M. Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill beta-cells. Diabetes 2012, 61:1752-1759.
25. van Halteren A.G., Kardol M.J., Mulder A., Roep B.O. Homing of human autoreactive T cells into pancreatic tissue of NOD-scid mice. Diabetologia 2005, 48:75-82.
26. + T-cells in HLA-A*0201 transgenic NOD mice. Diabetes 2007, 56:2551-2560.
27. Unger W.W., Pearson T., Abreu J.R., Laban S., van der Slik A.R., der Kracht S.M., Kester M.G., Serreze D.V., Shultz L.D., Griffioen M., Drijfhout J.W., Greiner D.L., Roep B.O. Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/SCID/IL2RG null mice. PLoS One 2012, 7:e49213.
28. + T-cell responses change after type 1 diabetes diagnosis and treatment. Diabetes 2008, 57:1312-1320.
29. Vendrame F., Pileggi A., Laughlin E., Allende G., Martin-Pagola A., Molano R.D., Diamantopoulos S., Standifer N., Geubtner K., Falk B.A., Ichii H., Takahashi H., Snowhite I., Chen Z., Mendez A., Chen L., Sageshima J., Ruiz P., Ciancio G., Ricordi C., Reijonen H., Nepom G.T., Burke G.W., Pugliese A. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010, 59:947-957.
30. Kulmala P., Savola K., Petersen J.S., Vahasalo P., Karjalainen J., Lopponen T., Dyrberg T., Akerblom H.K., Knip M. Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. J. Clin. Invest. 1998, 101:327-336.
31. Klinke D.J. Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One 2008, 3:e1374.
32. Greenbaum C.J., Mandrup-Poulsen T., McGee P.F., Battelino T., Haastert B., Ludvigsson J., Pozzilli P., Lachin J.M., Kolb H. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008, 31:1966-1971.
33. Roep B.O., Peakman M. Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat. Rev. Immunol. 2010, 10:145-152.
34. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., Schandene L., Crenier L., De B.C., Seigneurin J.M., De P.P., Pierard D., Weets I., Rebello P., Bird P., Berrie E., Frewin M., Waldmann H., Bach J.F., Pipeleers D., Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 2005, 352:2598-2608.
35. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., McGee P.F., Moran A.M., Raskin P., Rodriguez H., Schatz D.A., Wherrett D., Wilson D.M., Lachin J.M., Skyler J.S. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
36. Yu L., Herold K., Krause-Steinrauf H., McGee P.L., Bundy B., Pugliese A., Krischer J., Eisenbarth G.S. Rituximab selectively suppresses specific islet antibodies. Diabetes 2011, 60:2560-2565.
37. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., Vaarala O., Forsander G., Ivarsson S., Johansson C., Lindh A., Nilsson N.O., Aman J., Ortqvist E., Zerhouni P., Casas R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 2008, 359:1909-1920.
38. Axelsson S., Cheramy M., Hjorth M., Pihl M., Akerman L., Martinuzzi E., Mallone R., Ludvigsson J., Casas R. Long-lasting immune responses 4years after GAD-alum treatment in children with type 1 diabetes. PLoS One 2011, 6:e29008.
39. Reijonen H., Daniels T.L., Lernmark A., Nepom G.T. GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes 2000, 49:1621-1626.
40. Harrison L.C., Honeyman M.C., Steele C.E., Stone N.L., Sarugeri E., Bonifacio E., Couper J.J., Colman P.G. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004, 27:2348-2355.
41. Brezar V., Carel J.C., Boitard C., Mallone R. Beyond the hormone: insulin as an autoimmune target in type 1 diabetes. Endocr. Rev. 2011, 32:623-669.
42. Brezar V., Culina S., Gagnerault M.C., Mallone R. Short-term subcutaneous insulin treatment delays but does not prevent diabetes in NOD mice. Eur. J. Immunol. 2012, 42:1553-1561.
43. Britten C.M., Janetzki S., Butterfield L.H., Ferrari G., Gouttefangeas C., Huber C., Kalos M., Levitsky H.I., Maecker H.T., Melief C.J., O'Donnell-Tormey J., Odunsi K., Old L.J., Ottenhoff T.H., Ottensmeier C., Pawelec G., Roederer M., Roep B.O., Romero P., van der Burg S.H., Walter S., Hoos A., Davis M.M. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 2012, 37:1-2.
44. Mallone R., Mannering S.I., Brooks-Worrell B.M., Durinovic-Bello I., Cilio C.M., Wong F.S., Schloot N.C. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin. Exp. Immunol. 2011, 163:33-49.
45. Peakman M., Tree T.I., Endl J., van Endert P., Atkinson M.A., Roep B.O. Characterization of preparations of GAD65, proinsulin, and the islet tyrosine phosphatase IA-2 for use in detection of autoreactive T-cells in type 1 diabetes: report of phase II of the Second International Immunology of Diabetes Society Workshop for Standardization of T-cell assays in type 1 diabetes. Diabetes 2001, 50:1749-1754.
46. Roep B.O., Atkinson M.A., van Endert P.M., Gottlieb P.A., Wilson S.B., Sachs J.A. Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays. J. Autoimmun. 1999, 13:267-282.
47. Mannering S.I., Wong F.S., Durinovic-Bello I., Brooks-Worrell B., Tree T.I., Cilio C.M., Schloot N.C., Mallone R. Current approaches to measuring human islet-antigen specific T cell function in type 1 diabetes. Clin. Exp. Immunol. 2010, 162:197-209.
48. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J.A., McFarland H.F., Martin R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000, 6:1167-1175.
49. Davis M.M. A prescription for human immunology. Immunity 2008, 29:835-838.
50. Culina S., Boitard C., Mallone R. Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks?. Clin. Dev. Immunol. 2011, 2011:286248.
51. Fourlanos S., Perry C., Gellert S.A., Martinuzzi E., Mallone R., Butler J., Colman P.G., Harrison L.C. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 2011, 60:1237-1245.
52. Huurman V.A., van der Meide P.E., Duinkerken G., Willemen S., Cohen I.R., Elias D., Roep B.O. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin. Exp. Immunol. 2008, 152:488-497.
53. Thrower S.L., James L., Hall W., Green K.M., Arif S., Allen J.S., Van-Krinks C., Lozanoska-Ochser B., Marquesini L., Brown S., Wong F.S., Dayan C.M., Peakman M. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study. Clin. Exp. Immunol. 2009, 155:156-165.
54. Harlan D.M., Kenyon N.S., Korsgren O., Roep B.O. Current advances and travails in islet transplantation. Diabetes 2009, 58:2175-2184.
55. Roep B.O., Stobbe I., Duinkerken G., van Rood J.J., Lernmark A., Keymeulen B., Pipeleers D., Claas F.H., de Vries R.R. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999, 48:484-490.
56. Huurman V.A., Hilbrands R., Pinkse G.G., Gillard P., Duinkerken G., van de Linde P., van der Meer-Prins P.M., Versteeg-van der Voort Maarschalk M.F., Verbeeck K., Alizadeh B.Z., Mathieu C., Gorus F.K., Roelen D.L., Claas F.H., Keymeulen B., Pipeleers D.G., Roep B.O. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One 2008, 3:e2435.
57. Hilbrands R., Huurman V.A., Gillard P., Velthuis J.H., De Waele M., Mathieu C., Kaufman L., Pipeleers-Marichal M., Ling Z., Movahedi B., Jacobs-Tulleneers-Thevissen D., Monbaliu D., Ysebaert D., Gorus F.K., Roep B.O., Pipeleers D.G., Keymeulen B. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 2009, 58:2267-2276.
58. Huurman V.A., Velthuis J.H., Hilbrands R., Tree T.I., Gillard P., van der Meer-Prins P.M., Duinkerken G., Pinkse G.G., Keymeulen B., Roelen D.L., Claas F.H., Pipeleers D.G., Roep B.O. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am. J. Transplant. 2009, 9:382-388.
59. Stobbe I., Duinkerken G., van Rood J.J., Lernmark A., Keymeulen B., Pipeleers D., De Vries R.R., Glass F.H., Roep B.O. Tolerance to kidney allograft transplanted into type I diabetic patients persists after in vivo challenge with pancreatic islet allografts that express repeated mismatches. Diabetologia 1999, 42:1379-1380.
60. van Kampen C.A., van de Linde P., Duinkerken G., van Schip J.J., Roelen D.L., Keymeulen B., Pipeleers D.G., Claas F.H., Roep B.O. Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients. Transplantation 2005, 80:118-126.
61. Campbell P.M., Salam A., Ryan E.A., Senior P., Paty B.W., Bigam D., McCready T., Halpin A., Imes S., Al Saif F., Lakey J.R., Shapiro A.M. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am. J. Transplant. 2007, 7:1242-1248.
62. Campbell P.M., Senior P.A., Salam A., Labranche K., Bigam D.L., Kneteman N.M., Imes S., Halpin A., Ryan E.A., Shapiro A.M. High risk of sensitization after failed islet transplantation. Am. J. Transplant. 2007, 7:2311-2317.
63. Gillard P., Huurman V., Van der Auwera B., Decallonne B., Poppe K., Roep B.O., Gorus F., Mathieu C., Pipeleers D., Keymeulen B. Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic Islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care 2009, 32:1817-1819.
64. Bosi E., Braghi S., Maffi P., Scirpoli M., Bertuzzi F., Pozza G., Secchi A., Bonifacio E. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001, 50:2464-2471.
65. Jaeger C., Brendel M.D., Eckhard M., Bretzel R.G. Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation. Exp. Clin. Endocrinol. Diabetes 2000, 108:328-333.
66. Gillard P., Ling Z., Mathieu C., Crenier L., Lannoo M., Maes B., Roep B., Gorus F., Pipeleers D., Keymeulen B. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. Transplantation 2008, 85:256-263.
67. Roelen D.L., Huurman V.A., Hilbrands R., Gillard P., Duinkerken G., van der Meer-Prins P.W., Versteeg-van der Voort Maarschalk M.F., Mathieu C., Keymeulen B., Pipeleers D.G., Roep B.O., Claas F.H. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clin. Exp. Immunol. 2009, 156:141-148.
68. Monti P., Scirpoli M., Maffi P., Ghidoli N., De T.F., Bertuzzi F., Piemonti L., Falcone M., Secchi A., Bonifacio E. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J. Clin. Invest. 2008, 118:1806-1814.
69. Huurman V.A., van der Torren C.R., Gillard P., Hilbrands R., van der Meer-Prins E.P., Duinkerken G., Gorus F.K., Claas F.H., Keymeulen B., Roelen D.L., Pipeleers D.G., Roep B.O. Immune responses against islet allografts during tapering of immunosuppression-a pilot study in 5 subjects. Clin. Exp. Immunol. 2012, 169:190-198.
70. Skyler J.S., Krischer J.P., Wolfsdorf J., Cowie C., Palmer J.P., Greenbaum C., Cuthbertson D., Rafkin-Mervis L.E., Chase H.P., Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial-type 1. Diabetes Care 2005, 28:1068-1076.
71. Culina S., Mallone R. Pathogenic and regulatory T cells in type 1 diabetes: losing self-control, restoring it, and how to take the temperature. Curr. Diab. Rep. 2011, 11:426-433.
72. Tree T.I., Lawson J., Edwards H., Skowera A., Arif S., Roep B.O., Peakman M. Naturally arising human CD4 T cells that recognize islet autoantigens and secrete IL-10 regulate pro-inflammatory T cell responses via linked suppression. Diabetes 2010, 59:1451-1460.
73. Gaglia J.L., Guimaraes A.R., Harisinghani M., Turvey S.E., Jackson R., Benoist C., Mathis D., Weissleder R. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J. Clin. Invest. 2011, 121:442-445.
74. Ehses J.A., Perren A., Eppler E., Ribaux P., Pospisilik J.A., Maor-Cahn R., Gueripel X., Ellingsgaard H., Schneider M.K., Biollaz G., Fontana A., Reinecke M., Homo-Delarche F., Donath M.Y. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007, 56:2356-2370.
75. Medarova Z., Moore A. MRI as a tool to monitor islet transplantation. Nat. Rev. Endocrinol. 2009, 5:444-452.